Medication
Abbreviations: ATC, Anatomical Therapeutic Chemical Classification System. * The sample consists of the fathers with any antidepressant medication overlapping the conception period (A in Figure 1 ) or beginning in pregnancy (no antidepressant medication during conception; A in Figure 1 , but any antidepressant medication during pregnancy; B in Figure 1 ). cohort study. a Children of fathers with no antidepressant dispensation with a medication period overlapping either the conception period (A in Figure1) or the pregnancy (B in Figure 1 ).
b Children born to fathers who had any antidepressant medication overlapping the conception period (A in Figure 1) c Children born to fathers without any antidepressant medication during the conception period (A in Figure 1 ), but had any antidepressant medication overlapping the pregnancy period (B in Figure 1 ). cohort study. a Children of fathers with no antidepressant dispensation with a medication period overlapping either the conception period (A in Figure1) or the pregnancy (B in Figure 1 ). b Children born to fathers who had any antidepressant medication overlapping the conception period (A in Figure 1) c Children born to fathers without any antidepressant medication during the conception period (A in Figure 1 ), but had any antidepressant medication overlapping the pregnancy period (B in Figure 1 ).
d Additional 1,314 children with missing paternal information that was excluded from the main analyses. Figure 1) ; 2) 2,033 children born to fathers without any antidepressant medication during the conception period (A in Figure 1 ), but had any antidepressant medication overlapping the pregnancy period (B in Figure 1) ; and 3) 164,492 children born to fathers without any antidepressant medication during neither the conception period (A in Figure 1 ), nor during the pregnancy period (B in Figure 1 ).
The figure presents hazard ratios from analyses without covariate adjustment (Model 1) and from analyses adjusted for a number of covariates (Model 2) according to footnote b . for the outcomes autism spectrum disorder, autistic disorder, Intellectual disability, and mild to moderate intellectual disability, and odds ratios for the outcomes preterm birth and malformation, and two-sided 95% confidence intervals in children of fathers 1) with an antidepressant medication overlapping the conception period, or 2) no antidepressant medication overlapping the conception period but with antidepressant medication beginning during pregnancy, compared with children born to fathers without any antidepressant medication overlapping neither the conception period, nor the pregnancy period.
a Analyses without covariate adjustment.
b Analyses adjusted for birthdate, paternal and maternal age, maternal medication during pregnancy with psychotropic drugs, paternal and maternal education (eTable 4), and for any paternal and/or maternal diagnosis prior child birth within specific psychiatric disorder sub-groups (yes/no), including depression, anxiety disorders, substance use disorder, bipolar disorder, compulsive disorder, attention deficit hyperactive disorder (ADHD), autism spectrum disorder, intellectual disability, and schizophrenia (see eTable 3 for specific diagnosis codes). cohort study. eFigure 3. Description of extended conception exposure periods * * In the study, fathers were defined as using antidepressants during conception if they had any antidepressant medication overlapping the conception period (A), while fathers without medication overlapping the conception, but beginning during the pregnancy (B) was defined as starting their antidepressant medication during pregnancy. Fathers with no antidepressant medication neither during the conception period, nor during the pregnancy period was defined as not using antidepressants.
Example 1 (N=170,508) describes the original extensions of the periods. The conception period was defined as 4 weeks prior conception to 4 weeks after conception (A in example 1; N=3,983). The conception was allowed to overlap the beginning of pregnancy to account for a potential margin of error of ultrasound dating. This meant that the children could be conceived no earlier than 28 days (4 weeks) after July 1, 2005 (i.e. July 29, 2005), since the Swedish Prescribed Drug Register started July 1, 2005. The pregnancy was defined as from 4 weeks after conception to the childbirth (B in example 1; N=2,033). An additional 164,492 fathers were defined as not using antidepressants. Results from analyses using these periods are presented in Figure 2 and Figure 3 .
However, the strict definition of the exposure periods could allow misclassification. If a father dispensed a single antidepressant prescription just prior July 1, 2005 when the Swedish Prescribed Drug Register started, or if a father had a prescription for say 2 years before conception but stopped 5 weeks before conception, they would be classified as unexposed. The effect of the two aforementioned scenarios were examined in example 2 and example 3 below. Further, if a father had never taken an antidepressant but filled a prescription at week 3 post conception, he would be misclassified as exposed during conception. The effect of this aforementioned scenario was examined in example 4.
In example 2 the conception period was extended to 8 weeks prior conception. This meant that the children could be conceived no earlier than 56 days (8 weeks) after July 1, 2005 (i.e. August 27, 2005), since the Swedish Prescribed Drug Register started July 1, 2005. The shortened follow-up reduced the cohort size with 8,312 children (total N=162,196) . In example 2, the conception period (A) included 4,080 children, the pregnancy period (B) included 1,808 children, and 156,308 children was classified as unexposed. Results from analyses using these periods are presented in eFigure 4.
In example 3 the conception period was extended to 12 weeks prior conception. This meant that the children could be conceived no earlier 84 days (12 weeks) after July 1, 2005 (i.e. September 24, 2005), since the Swedish Prescribed Drug Register started July 1, 2005. The shortened follow-up reduced the cohort size with 16,521 children (total N=153,987). In example 2, the conception period (A) included 4,120 children, the pregnancy period (B) included 1,631 children, and 148,236 children was classified as unexposed. Results from analyses using these periods are presented in eFigure 5.
In example 4 the conception period began 4 weeks prior conception, as in the original analyses in example 1, but did not extend beyond the estimated conception date. As in example 1, this meant that the children could be conceived no earlier than 28 days (4 weeks) after July 1, 2005 (i.e. July 29, 2005), since the Swedish Prescribed Drug Register started July 1, 2005, and included the same number of children as the main analyses (N=170,508). In example 4, the conception period (A) included 3,585 children, the pregnancy period (B) included 2,429 children, and 164,494 children was classified as unexposed. Results from analyses using these periods are presented in eFigure 6. cohort study. eFigure 4. Analyses where the conception period extended from 8 weeks prior conception until 4 weeks after conception * Abbreviations: N, number of children. Est., estimate. CI, confidence interval. LL, lower limit. UL, upper limit. * In the study, fathers were defined as using antidepressants during conception if they had any antidepressant medication overlapping the conception period (A), while fathers without medication overlapping the conception, but beginning during the pregnancy (B) was defined as starting their antidepressant medication during pregnancy. Fathers with no antidepressant medication neither during the conception period, nor during the pregnancy period was defined as not using antidepressants.
However, the strict definition of the exposure periods could allow misclassification. If a father dispensed a single antidepressant prescription just prior July 1, 2005 when the Swedish Prescribed Drug Register started, or if a father had a prescription for say 2 years before conception but stopped 5 weeks before conception, they would be classified as unexposed. To examine the size and effect of this potential misclassification, we altered the conception periods in three additional sets of analyses.
In eFigure 4 the conception period was extended to 8 weeks prior conception (example 2 in eFigure 2). This meant that the children could be conceived no earlier than 56 days (8 weeks) after July 1, 2005 (i.e. August 27, 2005), since the Swedish Prescribed Drug Register started July 1, 2005. The shortened follow-up reduced the cohort size with 8,312 children (total N=162,196) . In example 2, the conception period (A) included 4,080 children, the pregnancy period (B) included 1,808 children, and 156,308 children was classified as unexposed.
b Analyses adjusted for birthdate, paternal and maternal age, maternal medication during pregnancy with psychotropic drugs, paternal and maternal education (eTable 4), and for any paternal and/or maternal diagnosis prior child birth within specific psychiatric disorder sub-groups (yes/no), including depression, anxiety disorders, substance use disorder, bipolar disorder, compulsive disorder, attention deficit hyperactive disorder (ADHD), autism spectrum disorder, intellectual disability, and schizophrenia (see eTable 3 for specific diagnosis codes). cohort study. eFigure 5. Analyses where the conception period extended from 12 weeks prior conception until 4 weeks after conception * Abbreviations: N, number of children. Est., estimate. CI, confidence interval. LL, lower limit. UL, upper limit. * In the study, fathers were defined as using antidepressants during conception if they had any antidepressant medication overlapping the conception period (A), while fathers without medication overlapping the conception, but beginning during the pregnancy (B) was defined as starting their antidepressant medication during pregnancy. Fathers with no antidepressant medication neither during the conception period, nor during the pregnancy period was defined as not using antidepressants.
In eFigure 5 the conception period was extended to 8 weeks prior conception (example 3 in eFigure 2). This meant that the children could be conceived no earlier 84 days (12 weeks) after July 1, 2005 (i.e. September 24, 2005), since the Swedish Prescribed Drug Register started July 1, 2005. The shortened follow-up reduced the cohort size with 16,521 children (total N=153,987). In example 2, the conception period (A) included 4,120 children, the pregnancy period (B) included 1,631 children, and 148,236 children was classified as unexposed.
b Analyses adjusted for birthdate, paternal and maternal age, maternal medication during pregnancy with psychotropic drugs, paternal and maternal education (eTable 4), and for any paternal and/or maternal diagnosis prior child birth within specific psychiatric disorder sub-groups (yes/no), including depression, anxiety disorders, substance use disorder, bipolar disorder, compulsive disorder, attention deficit hyperactive disorder (ADHD), autism spectrum disorder, intellectual disability, and schizophrenia (see eTable 3 for specific diagnosis codes). cohort study. eFigure 6. Analyses where the conception period extended from 4 weeks prior conception until conception * Abbreviations: N, number of children. Est., estimate. CI, confidence interval. LL, lower limit. UL, upper limit. * In the study, fathers were defined as using antidepressants during conception if they had any antidepressant medication overlapping the conception period (A), while fathers without medication overlapping the conception, but beginning during the pregnancy (B) was defined as starting their antidepressant medication during pregnancy. Fathers with no antidepressant medication neither during the conception period, nor during the pregnancy period was defined as not using antidepressants.
However, the strict definition of the exposure periods could allow misclassification. If a father had never taken an antidepressant but filled a prescription at week 3 post conception, he would be misclassified as exposed during conception. To examine the size and effect of this potential misclassification, we altered the conception periods in three additional sets of analyses.
In eFigure 6 the conception period began 4 weeks prior conception, as in the original analyses in Figure 2 , but did not extend beyond the estimated conception date (example 4 in eFigure 2). As in Figure 2 , this meant that the children could be conceived no earlier than 28 days (4 weeks) after July 1, 2005 (i.e. July 29, 2005), since the Swedish Prescribed Drug Register started July 1, 2005, and included the same number of children as the main analyses (N=170,508). In example 4, the conception period (A) included 3,585 children, the pregnancy period (B) included 2,429 children, and 164,494 children was classified as unexposed.
The figure presents hazard ratios from analyses without covariate adjustment (Model 1) and from analyses adjusted for a number of covariates (Model 2) according to footnote b . for the outcomes autism spectrum disorder, autistic disorder, Intellectual disability, and mild to moderate intellectual disability, and odds ratios for the outcomes preterm birth and malformation, and two-sided 95% confidence intervals in children of fathers 1) with an antidepressant medication overlapping the conception period, or 2) no antidepressant medication overlapping the conception period but with antidepressant medication beginning during pregnancy, compared with children born to fathers without any antidepressant medication overlapping neither the conception period, nor the pregnancy period. a Analyses without covariate adjustment.
b Analyses adjusted for birthdate, paternal and maternal age, maternal medication during pregnancy with psychotropic drugs, paternal and maternal education (eTable 4), and for any paternal and/or maternal diagnosis prior child birth within specific psychiatric disorder sub-groups (yes/no), including depression, anxiety disorders, substance use disorder, bipolar disorder, compulsive disorder, attention deficit hyperactive disorder (ADHD), autism spectrum disorder, intellectual disability, and schizophrenia (see eTable 3 for specific diagnosis codes). cohort study. Figure 1) ; 2) 1,389 children born to fathers without any antidepressant medication during the conception period (A in Figure 1 ), but had an SSRI antidepressant medication overlapping the pregnancy period (B in Figure 1) ; and 3) 164,492 children born to fathers without any antidepressant medication during neither the conception period (A in Figure 1 ), nor during the pregnancy period (B in Figure 1 ).
b Analyses adjusted for birthdate, paternal and maternal age, maternal medication during pregnancy with psychotropic drugs, paternal and maternal education (eTable 4), and for any paternal and/or maternal diagnosis prior child birth within specific psychiatric disorder sub-groups (yes/no), including depression, anxiety disorders, substance use disorder, bipolar disorder, compulsive disorder, attention deficit hyperactive disorder (ADHD), autism spectrum disorder, intellectual disability, and schizophrenia (see eTable 3 for specific diagnosis codes). cohort study. Figure 1 ) with one of the four most common SSRI antidepressants in the cohort (conception); 2) 1,389 children born to fathers without any antidepressant medication during the conception period (A in Figure 1 ), but had SSRI antidepressant medication overlapping the pregnancy period (B in Figure 1 ) with one of the four most common SSRI antidepressants in the cohort (pregnancy); and 3) 164,492 children born to fathers without any antidepressant medication (neither SSRI, nor non-SSRI) during neither the conception period (A in Figure 1 ), nor during the pregnancy period (B in Figure 1 ) (unexposed).
b Analyses adjusted for birthdate, paternal and maternal age, maternal medication during pregnancy with psychotropic drugs, paternal and maternal education (eTable 4), and for any paternal and/or maternal diagnosis prior child birth within specific psychiatric disorder sub-groups (yes/no), including depression, anxiety disorders, substance use disorder, bipolar disorder, compulsive disorder, attention deficit hyperactive disorder (ADHD), autism spectrum disorder, intellectual disability, and schizophrenia (see eTable 3 for specific diagnosis codes). cohort study. Figure 1 ) but without concomitant medication with other nonantidepressant psychotropic drugs overlapping the conception period (A in Figure 1 ) or during the pregnancy period (B in Figure 1) ; 2) 1,305 children born to fathers without any antidepressant medication or non-antidepressant psychotropic drugs during the conception period (A in Figure 1 ), but with any antidepressant medication overlapping the pregnancy period (B in Figure 1 ) but without concomitant medication with other non-antidepressant psychotropic drugs overlapping the pregnancy period (B in Figure 1) ; and 3) 165,944 children born to fathers without any psychotropic medication during neither the conception period (A in Figure 1) , nor during the pregnancy period (B in Figure 1 ).
b Analyses adjusted for birthdate, paternal and maternal age, maternal medication during pregnancy with psychotropic drugs, paternal and maternal education (eTable 4), and for any paternal and/or maternal diagnosis prior child birth within specific psychiatric disorder sub-groups (yes/no), including depression, anxiety disorders, substance use disorder, bipolar disorder, compulsive disorder, attention deficit hyperactive disorder (ADHD), autism spectrum disorder, intellectual disability, and schizophrenia (see eTable 3 for specific diagnosis codes). cohort study. Figure 1) ; 2) 2,033 children born to fathers without any antidepressant medication during the conception period (A in Figure 1 ), but had any antidepressant medication overlapping the pregnancy period (B in Figure 1) ; and 3) 164,492 children born to fathers without any antidepressant medication during neither the conception period (A in Figure 1) , nor during the pregnancy period (B in Figure 1 ).
The figure presents hazard ratios from analyses without covariate adjustment (Model 1) and from analyses adjusted for a number of covariates (Model 2) according to footnote b . for the outcomes autism spectrum disorder, autistic disorder, Intellectual disability, and mild to moderate intellectual disability, and odds ratios for the outcomes preterm birth and malformation, and two-sided 95% confidence intervals in children of fathers 1) with an antidepressant medication overlapping the conception period, or 2) no antidepressant medication overlapping the conception period but with antidepressant medication beginning during pregnancy, compared with children born to fathers without any antidepressant medication overlapping neither the conception period, nor the pregnancy period. Bootstrapping was performed with 200 repetitions.
For the chosen analytical procedure, analyzing time-to-event data by Cox regression, a model assumption is that the data can be considered independent (conditional on the model covariates). Although our study has limited birth follow-up period, the variances may be biased if there are non-independent observations, (e.g. through multiple pregnancies per father). However, even though the variances may be biased, the point estimates are still unbiased. Therefore, bootstrapping can be applied to address potential problems due to non-independent observations. By bootstrapping the data, we are creating a sequence of unbiased point estimates which can be combined using common statistical methods (Efron B, Tibshirani RJ. An Introduction to the Bootstrap. 1st ed. Chapman and Hall/CRC 1994). An alternative and comparable procedure is to calculate robust standard errors ("Sandwich estimator") which, similar to bootstrapping, also assume and utilize unbiased point estimates. Another approach would be to include random effects to model the assumed correlations in the data. a Analyses without covariate adjustment.
b Analyses adjusted for birthdate, paternal and maternal age, maternal medication during pregnancy with psychotropic drugs, paternal and maternal education (eTable 4), and for any paternal and/or maternal diagnosis prior child birth within specific psychiatric disorder sub-groups (yes/no), including depression, anxiety disorders, substance use disorder, bipolar disorder, compulsive disorder, attention deficit hyperactive disorder (ADHD), autism spectrum disorder, intellectual disability, and schizophrenia (see eTable 3 for specific diagnosis codes). cohort study. eFigure 11 Risks of adverse outcomes in children born to fathers with any antidepressant medication during conception, or beginning during pregnancy excluding children born to mothers with any psychotropic medication overlapping pregnancy* Abbreviations: N, number of children. Est., estimate. CI, confidence interval. LL, lower limit. UL, upper limit.
* The sample consists of 161,5620 children conceived from July 29, 2005 and born during 2006 and 2007 and excludes any children born to mothers with any psychotropic medication overlapping the pregnancy, and includes: 1) 3,468 children born to fathers who had any antidepressant medication overlapping the conception period (A in Figure 1) ; 2) 1,799 children born to fathers without any antidepressant medication during the conception period (A in Figure 1 ), but had any antidepressant medication overlapping the pregnancy period (B in Figure 1) ; and 3) 156,353 children born to fathers without any antidepressant medication during neither the conception period (A in Figure 1) , nor during the pregnancy period (B in Figure 1 ).
b Analyses adjusted for birthdate, paternal and maternal age, maternal medication during pregnancy with psychotropic drugs, paternal and maternal education (eTable 4), and for any paternal and/or maternal diagnosis prior child birth within specific psychiatric disorder sub-groups (yes/no), including depression, anxiety disorders, substance use disorder, bipolar disorder, compulsive disorder, attention deficit hyperactive disorder (ADHD), autism spectrum disorder, intellectual disability, and schizophrenia (see eTable 3 for specific diagnosis codes). cohort study.
eFigure 12 Sex-specific and sex-combined risks of adverse outcomes in children born to fathers with any antidepressant medication during conception, or beginning during pregnancy* Abbreviations: N, number of children. Est., estimate. CI, confidence interval. LL, lower limit. UL, upper limit. Figure 1) ; 2) 2,033 children born to fathers without any antidepressant medication during the conception period (A in Figure 1 ), but had any antidepressant medication overlapping the pregnancy period (B in Figure 1) ; and 3) 164,492 children born to fathers without any antidepressant medication during neither the conception period (A in Figure 1 ), nor during the pregnancy period (B in Figure 1 ).
The figure presents hazard ratios for the outcomes autism spectrum disorder, autistic disorder, Intellectual disability, and mild to moderate intellectual disability, and odds ratios for the outcomes preterm birth and malformation, and two-sided 95% confidence intervals in children of fathers 1) with an antidepressant medication overlapping the conception period, or 2) no antidepressant medication overlapping the conception period but with antidepressant medication beginning during pregnancy, compared with children born to fathers without any antidepressant medication overlapping neither the conception period, nor the pregnancy period. Figure 2 , and are adjusted for birthdate, paternal and maternal age, maternal medication during pregnancy with psychotropic drugs, paternal and maternal education (eTable 4), and for any paternal and/or maternal diagnosis prior child birth within specific psychiatric disorder sub-groups (yes/no), including depression, anxiety disorders, substance use disorder, bipolar disorder, compulsive disorder, attention deficit hyperactive disorder (ADHD), autism spectrum disorder, intellectual disability, and schizophrenia (see eTable 3 for specific diagnosis codes). cohort study. eFigure 14 Risks of adverse outcomes in children born to fathers with any antidepressant medication during conception (at least 2 antidepressant dispensations within 6 months from the conception date), or beginning during pregnancy Abbreviations: N, number of children. Est., estimate. CI, confidence interval. LL, lower limit. UL, upper limit. Figure 1 ) and at least 2 antidepressant dispensations within 6 months of the conception date; 2) 2,033 children born to fathers without any antidepressant medication during the conception period (A in Figure 1 ), but had any antidepressant medication overlapping the pregnancy period (B in Figure 1) ; and 3) 164,492 children born to fathers without any antidepressant medication during neither the conception period (A in Figure 1 ), nor during the pregnancy period (B in Figure 1 ).
All analyses represent Model 2 in
b Analyses adjusted for birthdate, paternal and maternal age, maternal medication during pregnancy with psychotropic drugs, paternal and maternal education (eTable 4), and for any paternal and/or maternal diagnosis prior child birth within specific psychiatric disorder sub-groups (yes/no), including depression, anxiety disorders, substance use disorder, bipolar disorder, compulsive disorder, attention deficit hyperactive disorder (ADHD), autism spectrum disorder, intellectual disability, and schizophrenia (see eTable 3 for specific diagnosis codes). cohort study. The sample includes: 1) 675 children born to fathers who had any antidepressant medication overlapping the conception period (A in Figure 1 ) (conception); 2) 1,073 children born to fathers without any antidepressant medication during the conception period (A in Figure  1 ), but had any antidepressant medication overlapping the pregnancy period (B in Figure 1 ) (pregnancy); and 3) 111,675 children born to fathers without any antidepressant medication during neither the conception period (A in Figure 1 ), nor during the pregnancy period (B in Figure 1 ) (unexposed).
Studying only at new medications may offer insights to the role of the underlying characteristics and severity of the indication for which antidepressants are prescribed. However, this solution has general limitations in regard to the main research question of the study; is antidepressant exposure during conception associated with adverse outcomes. In the original analysis, we show that among the fathers with antidepressant medication during conception, 86.6% have another dispensation of an antidepressant within 6 months, suggesting that a majority are on a continuous medication. This is important as the exact compliance in observational studies of pharmacological treatment cannot be perfectly ascertained. However, the continuous medication pattern, at least to us, suggest that the majority was likely using the medication at the time of conception. This, however, likely also make the groups different in regard of stability/severity of the underlying condition that require antidepressant treatment. Yet, by confining the analysis to fathers with a new antidepressant treatment we will exclude most fathers who were on a continuous medication treatment. Consequently, we will lose a major strength of the original analysis regarding continuity of treatment as a potential marker of medication compliance during the period when the sperm could be affected by the drug.
Beside the general issues with this approach discussed above, there are also limitations specific to the design of our cohort. Our narrow period of childbirths has a strength in that it reduces confounding due to factors that vary with time (e.g. detection of offspring diagnoses). However, the short time window makes additional analyses that require expansion of the preconceptual period difficult. To make sure the medication was part of a new treatment, we had to add a period prior conception where we could capture medication dispensations. As the Swedish Prescribed Drug Register began July 1, 2005, this meant that we had to restrict the cohort to children conceived later during follow up. This, naturally, reduce number of children included and the power of the analyses.
By limiting the cohort in this way, the cohort was reduced to 113,423 children, a reduction of the cohort size by 33.5%. The number of fathers/offspring with antidepressant medication during conception was also drastically reduced from 3,983 to 675 (a reduction by 83.0%), which was expected as most fathers in the original analysis were on a continuous medication treatment. However, there was also a reduction of fathers who began antidepressant treatment during pregnancy; from 2,033 to 1,073 (a reduction by 47,2%), which is slightly more than what could be expected from the reduced overall cohort size ( -33.5%). Still, the reduction in the group of fathers beginning antidepressant treatment during pregnancy was much smaller than the reduction among fathers with antidepressants during conception, further supporting that the two groups had inherent differences that could be due to incident depression or a worsening to trigger a prescription.
b Analyses adjusted for birthdate, paternal and maternal age, maternal medication during pregnancy with psychotropic drugs, paternal and maternal education (eTable 4), and for any paternal and/or maternal diagnosis prior child birth within specific psychiatric disorder sub-groups (yes/no), including depression, anxiety disorders, substance use disorder, bipolar disorder, compulsive disorder, attention deficit hyperactive disorder (ADHD), autism spectrum disorder, intellectual disability, and schizophrenia (see eTable 3 for specific diagnosis codes).
